Introduction: Cardiovascular disease is the leading cause of death in non-alcoholic fatty liver disease, but there is limited data on outcomes for interventions with NASH cirrhosis and cardiac disease. We aim to assess rates and outcomes of percutaneous coronary intervention (PCI) in NASH cirrhosis (NASH+) vs. non-NASH cirrhosis (NASH-). Methods: Demographics, liver disease etiology, and cardiovascular risk factors were extracted from the National Inpatient Sample database, 2004 to 2014. Patients with cirrhosis receiving PCI were included for analysis. Acute coronary syndrome (ACS) was defined as having ST-elevation myocardial infarction (STEMI), non-STEMI, or unstable angina. Illness severity (Elixhauser index), mortality, hospital cost, and length of stay were also extracted. We calculated chi-square and Mann-Whitney tests for categorical and continuous variables, respectively. Linear and logistic regression was performed to assess associations with mortality in NASH+ and NASH- patients. Results: Of 1,104,723 hospitalizations with cirrhosis, 3,855 patients received PCI, with 752 had ACS. 46.1% were NASH+, and 53.9% NASH-. The rate of PCI in NASH+ patients was nearly double that of NASH- (4.72 vs. 2.43 PCIs per 1,000 patients, p<0.0001). NASH+ patients receiving PCI were more often female, with Medicare insurance, had hypertension, and hospitalized in the Northeast and South. NASH+ patients had significantly lower mortality, decompensated cirrhosis, tobacco use, disease severity, and shorter hospitalization duration. Univariate analysis revealed lower odds of mortality in NASH+ compared to NASH- (OR 0.69, p=0.018), and lower hospital costs and lengths of stay. After multivariable adjustment, this finding became non-significant (OR 1.43, p=0.419), but female gender and Southern region (vs. North) still predicted post-PCI mortality (OR = 7.18, p<0.0001, and OR = 5.10, p = 0.025, respectively). In this model, patients in the lowest income quartile and with coronary artery disease had improved post-PCI survival outcomes (OR 0.16, p=0.008; OR 0.22, p=0.002). Conclusion: More hospitalized patients with NASH cirrhosis receive PCI, compared to non-NASH cirrhosis. NASH cirrhosis is associated with increased mortality with PCI, but this effect disappears with adjustment for cardiac risk factors. Demographic differences are observed, with higher mortality in women, and hospitalizations in the Southern United States.1004_A Figure 1 No Caption available.1004_B Figure 2 No Caption available.